Autoban Acquisition

Autobahn Therapeutics is a clinical-stage biotechnology company focused on developing restorative treatments for neuropsychiatric and neuroimmunologic disorders. The company leverages its proprietary brain-targeting chemistry platform to deliver small molecules across the blood-brain barrier with precision, aiming to improve central nervous system (CNS) exposure while minimizing peripheral side effects. Its lead candidate, elunetirom (ABX-002), is a potent and selective thyroid hormone receptor beta (TRβ) agonist currently in Phase 2 clinical trials for the adjunctive treatment of major depressive disorder (MDD) and bipolar depression. Additionally, the company is advancing ABX-101, a brain-penetrant S1P receptor modulator, for neuroinflammatory conditions. Autobahn is backed by a strong syndicate of investors, including ARCH Venture Partners, Pfizer Ventures, and Biogen.